Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
2
Neutral
8
Bullish
4
Bearish
29
Neutral
8
Bullish
9
Bearish
27
Neutral
0
Bullish
5
Upcoming Result Date: May 06, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Earnings Call Notice
Board meeting scheduled May 7, 2026 to approve audited standalone and consolidated results for Q4/FY ended Mar 31, 2026; earnings conference call for analysts on May 8, 2026 at 09:00 IST (Zoom); trading window closed Apr 1–May 9.
Earnings Call Notice
Biocon will hold a Board meeting on May 7, 2026 to approve audited standalone and consolidated Q4/FY2025-26 results and host an earnings conference call for analysts/investors on May 8, 2026 at 09:00 IST (trading window closed Apr 1–May 9).
Earnings announcement
Biocon will hold a Board meeting on May 7, 2026 to approve audited standalone & consolidated results for Q4/FY26 and consider dividend; trading window closed Apr 1–May 9; earnings conference call scheduled May 8, 2026 at 09:00 IST.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Biocon Ltd (BIOCON) is currently trading at 357.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹308.80 and a high of ₹424.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 58,725.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 97.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 58,725.49 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 97.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biocon said Health Canada approved its denosumab biosimilar drugs Bosaya and Vevzuo on April 3, 2026.
Health Canada granted a Notice of Compliance for Bosaya (denosumab), a biosimilar to Prolia, and Vevzuo (denosumab), a biosimilar to Xgeva.
Dapagliflozin is a medication used to improve blood sugar control in adults with type-2 diabetes. It is also used to reduce the risk of hospitalization for heart failure in these patients. It is the generic version of AstraZeneca's brand-name drug, Farxiga.
Bosaya™ and Aukelso™ are biosimilar drugs developed by Biocon. They are nearly identical copies of the biologic medicines Prolia® and Xgeva®, respectively, and are used to treat osteoporosis and cancer-related bone conditions.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2161.50 | 68,027 Cr | 63.87 | 7.10 | 0.10 | 26.24 | 30.84 | 5.60 | ||
5605.20 | 63,883 Cr | 26.94 | 4.79 | 0.84 | 17.69 | 18.13 | 11.95 | ||
1129.60 | 59,692 Cr | 70.78 | 12.42 | 0.11 | 14.23 | 15.05 | 8.94 | ||
350.55 | 58,725 Cr | 97.20 | 1.55 | 0.10 | 1.81 | 4.20 | 1.00 | ||
25931.95 | 54,155 Cr | 35.53 | 13.50 | 1.86 | 37.62 | 48.38 | 26.77 | ||
2451.80 | 40,166 Cr | 39.34 | 23.52 | 2.28 | 55.94 | 74.64 | 27.86 | ||
1439.00 | 39,115 Cr | 42.99 | 5.27 | 0.26 | 13.33 | 17.89 | 7.73 | ||
| Median: 7 Co. | — | 2161.50 | 58,725 Cr | 42.99 | 7.10 | 0.26 | 17.69 | 18.13 | 8.94 |
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.
The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.
Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus.
Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Pharmaceuticals & Biotechnology
Pharmaceuticals
57,866 Cr
Low Risk
95.8
33.2
0.9
1.6
424.95
308.80
Sales CAGR
Profit CAGR
ROE
ROCE
